The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Abstract
Two thousand three hundred and thirty two nonselected brains from 1- to 100-year-old individuals were examined using immunocytochemistry (AT8) and Gallyas silver staining for abnormal tau; immunocytochemistry (4G8) and Campbell-Switzer staining were used for the detection ofβ-amyloid. A total of 342 cases was negative in the Gallyas stain but when restaged for AT8 only 10 were immunonegative. Fifty-eight cases had subcortical tau predominantly in the locus coeruleus, but there was no abnormal cortical tau (subcortical Stages a-c). Cortical involvement (abnormal tau in neurites) was identified first in the transentorhinal region (Stage 1a, 38 cases). Transentorhinal pyramidal cells displayed pretangle material (Stage 1b, 236 cases). Pretangles gradually became argyrophilic neurofibrillary tangles (NFTs) that progressed in parallel with NFT Stages I to VI. Pretangles restricted to subcortical sites were seen chiefly at younger ages. Of the total cases, 1,031 (44.2%) had β-amyloid plaques. The first plaques occurred in the neocortex after the onset of tauopathy in the brainstem. Plaques generally developed in the 40s in 4% of all cases, culminating in their tenth decade (75%). β-amyloid plaques and NFTs were significantly correlated (p < 0.0001). These data suggest that tauopathy associated with sporadic Alzheimer disease may begin earlier than previously thought and possibly in the lower brainstem rather than in the transentorhinal region.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Up to 60% of CU individuals over age 80 years have AD neuropathologic changes at autopsy or by biomarkers [60,152,212–214].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [213]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“screening revealed low rates of Braak 1–2 NFT stages in all three groups (Table 2), consistent with literature-based norms [3].”
From Tuberous sclerosis complex is associated with a novel human tauopathy (2023) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It should be noted that tau aggregation in the brain is associated with older age and is generally uncommon in healthy young adults (Braak et al., 2011; Crary et al., 2014).”
From Tauopathy and Epilepsy Comorbidities and Underlying Mechanisms (2022) · cites this paper as Braak et al., 2011
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“It is expected that many persons die with brains that exhibit AD neuropathologic change in the preclinical phase of AD; indeed, data support the modeled expectations (44, 142).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“Medial temporal and brainstem neurofibrillary changes were observed in our older TSC subjects, as expected, but at a rate comparable to that observed in the epilepsy and non-neurological control groups and age-based norms [3].”
From Tuberous sclerosis complex is associated with a novel human tauopathy (2023) · cites this paper as [3]
In the citing paper
“In individuals with autosomal dominant mutations in genes coding for amyloid precursor protein (APP) or Presenilin 119 , alterations in Aβ generation that result in early deposition of plaque initiate the disease and patients invariably develop the full spectrum of tau pathology 120,121 .”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [121]
In the citing paper
“NFTs first appear in layer II of the entorhinal cortex (EC) during AD onset.”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [231]
In the citing paper
“NFTs subsequently appear in interconnected anatomical regions within the brain, including the hippocampus and neocortex during neurodegenerative progression [229–231].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [231]
In the citing paper
“Furthermore, it impairs adult hippocampal neurogenesis in mice and affects cortical thickness, brain activity, and mitochondrial function well before significant Aβ accumulation in the human brains [74–76].”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [76]
In the citing paper
“Most of all, this binary threshold does not reflect the reality of amyloid β and tau pathology, which is continuous and present at a minimal extent in almost all people older than 70 years,17 with important discrepancies between pathology burden and clinical symptoms at intermediate extents (panel 2).”
From Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group (2021) · cites this paper as [17]
In the citing paper
“For tau biomarkers, there is also a strong discrepancy between neuropathological identification (in post-mortem studies, the presence of tau Braak stages I–II is almost universal after age 70 years)17,19 and in-vivo measures of tau aggregates on PET (36% of individuals are tau positive after the age of 70 years23).”
From Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group (2021) · cites this paper as [17]
In the citing paper
“The concordance of genetics and Aβ deposition is aligned with CPC studies that indicate that AβPs may be a temporally “upstream” feature of the neocortical disease, with the caveats that brainstem and medial temporal lobe pretangles and NFTs are seen in subjects without Aβ deposition in all age categories (33, 39, 44).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [44]
In the citing paper
“In contrast to NFTs, AβPs are extracellular (45, 46) and are found in a high proportion of all elderly persons but are not universal (44, 47, 48).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [44]
In the citing paper
“Recently, it has been reported that NFTs are also very common in certain brainstem nuclei in subjects without dementia (39-44).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [44]
In the citing paper
“Neurofibrillary pathology is observed in the human brain long before Aβ plaques develop (39, 44, 300).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [44]
In the citing paper
“Neuritic plaques seem to develop after diffuse AβPs and NFTs (44).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [44]
In the citing paper
“At 40 years, all individuals studied by Braak and Del Tredici (39) and Braak et al (44) exhibited at least initial neurofibrillary pathology in the brainstem (Fig. 5).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 2×
“The first lesions were usually seen in the transentorhinal region (2).”
BackgroundSelf-citationThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Self-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Aston-Jones, G., & Cohen, J. D. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135709 · Cited by 4,472
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Self-citationBraak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Self-citationA Century of Alzheimer's Disease
Goedert, M., & Spillantini, M. G. (2006) · Science · doi:10.1126/science.1132814 · Cited by 2,153
The locus coeruleus and noradrenergic modulation of cognition
Sara, S. J. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2573 · Cited by 1,848
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
Self-citation
Cited by
Sorted by citations
Items 301–400 of 1,010
Ritchie, K. A., Carrière, I., Su, L., O'Brien, J. T., Lovestone, S., Wells, K., & Ritchie, C. W. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.02.008 · Cited by 108
DNA methylation signature of human hippocampus in Alzheimer’s disease is linked to neurogenesis
Altuna, M., Urdánoz‐Casado, A., de Gordoa, J. S., Zelaya, M. V., Labarga, A., Lepesant, J. M. J., Roldán, M., Blanco‐Luquin, I., Perdones-Montero, Á., Larumbe, R., et al. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0672-7 · Cited by 107
O’Dell, R. S., Mecca, A. P., Chen, M.-K., Naganawa, M., Toyonaga, T., Lu, Y., Godek, T. A., Harris, J. E., Bartlett, H. H., Banks, E. R., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00742-y · Cited by 107
Computational methods of EEG signals analysis for Alzheimer’s disease classification
Vicchietti, M. L., Ramos, F. M., Betting, L. E., & Campanharo, A. S. L. O. (2023) · Scientific Reports · doi:10.1038/s41598-023-32664-8 · Cited by 107
Longitudinal brain structural changes in preclinical Alzheimer's disease
Pegueroles, J., Vilaplana, E., Montal, V., Sampedro, F., Alcolea, D. A., Carmona‐Iragui, M., Clarimón, J., Blesa, R., Lleó, A., Fortea, J., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.08.010 · Cited by 106
Prion-like Spreading in Tauopathies
Ayers, J. I., Giasson, B. I., & Borchelt, D. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.04.003 · Cited by 106
Jacobs, H. I. L., Riphagen, J. M., Ramakers, I. H. G. B., & Verhey, F. R. J. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0437-x · Cited by 106
A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment
Levey, A. I., Qiu, D., Zhao, L., Hu, W. T., Duong, D. M., Higginbotham, L. A., Dammer, E. B., Seyfried, N. T., Wingo, T. S., Hales, C. M., et al. (2021) · Brain · doi:10.1093/brain/awab452 · Cited by 106
How Can Insulin Resistance Cause Alzheimer’s Disease?
Yoon, J. H., Hwang, J., Son, S. U., Choi, J., You, S.-W., Park, H., Cha, S.-Y., & Maeng, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043506 · Cited by 106
Brain pathologies in extreme old age
Neltner, J. H., Abner, E. L., Jicha, G. A., Schmitt, F. A., Patel, E., Poon, L. W., Marla, G., Green, R. C., Davey, A., Johnson, M. A., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.10.009 · Cited by 106
Tomé, S. O., Vandenberghe, R. R., Ospitalieri, S., Schoor, E. V., Tousseyn, T., Otto, M., Arnim, C. A. F. V., & Thal, D. R. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00934-5 · Cited by 105
Self-citationBraak, H., & Tredici, K. D. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1356-1 · Cited by 105
Self-citationImaging of Synaptic Density in Neurodegenerative Disorders
Carson, R. E., Naganawa, M., Toyonaga, T., Koohsari, S., Yang, Y., Chen, M.-K., Matuskey, D., & Finnema, S. J. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263201 · Cited by 104
Pathogenesis and Disease-modifying Therapy in Alzheimer's Disease: The Flat Line of Progress
Castellani, R. J., & Perry, G. L. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.09.009 · Cited by 104
Characteristics of Tau and Its Ligands in PET Imaging
Harada, R., Okamura, N., Furumoto, S., Tago, T., Yanai, K., Arai, H., & Kudo, Y. (2016) · Biomolecules · doi:10.3390/biom6010007 · Cited by 104
Impact of tau and amyloid burden on glucose metabolism in Alzheimer's disease
Bischof, G. N., Jessen, F., Fließbach, K., Dronse, J., Hammes, J., Neumaier, B., Onur, O. A., Fink, G. R., Kukolja, J., Drzezga, A. E., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.339 · Cited by 104
Neurodegenerative disorders and gut-brain interactions
Singh, A., Dawson, T. M., & Kulkarni, S. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143775 · Cited by 104
Current Concepts of Mixed Pathologies in Neurodegenerative Diseases
Forrest, S. L., & Kovács, G. G. (2022) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2022.34 · Cited by 104
A critical review of chronic traumatic encephalopathy
Iverson, G. L., Gardner, A. J., McCrory, P., Zafonte, R., & Castellani, R. J. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.05.008 · Cited by 103
Li, H., Liu, C.-C., Zheng, H., & Huang, T. Y. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0139-3 · Cited by 103
Hertz, L., Chen, Y., & Waagepetersen, H. S. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13107 · Cited by 103
Iverson, G. L., Gardner, A. J., Shultz, S. R., Solomon, G. S., McCrory, P. R., ZAFONTE, R. D., Perry, G. L., Hazrati, L., Keene, C. D., & Castellani, R. J. (2019) · Brain · doi:10.1093/brain/awz286 · Cited by 105
Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers
Soontornniyomkij, V., Moore, D. J., Gouaux, B. D., Soontornniyomkij, B., Tatro, E. T., Umlauf, A., Masliah, E., Levine, A. J., Singer, E. J., Vinters, H. V., et al. (2012) · AIDS · doi:10.1097/qad.0b013e32835a117c · Cited by 102
Neuro-degeneration profile of Alzheimer's patients: A brain morphometry study
Filho, S. R. B. D. S., Barbosa, J. H. O., Rondinoni, C., dos Santos, A. C., Salmón, C. E. G., Lima, N. K. D. C., Ferriolli, E., & Moriguti, J. C. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.04.001 · Cited by 102
Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities
Visanji, N. P., Lang, A. E., & Kovács, G. G. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0172-x · Cited by 102
Pyroglutamate Aβ cascade as drug target in Alzheimer’s disease
Bayer, T. A. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01409-2 · Cited by 102
Venkataraman, A. V., Mansur, A., Rizzo, G., Bishop, C., Lewis, Y., Kocagoncu, E., Lingford-Hughes, A., Huiban, M., Passchier, J., Rowe, J. B., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abk1051 · Cited by 101
Ercan-Herbst, E., Ehrig, J., Schöndorf, D. C., Behrendt, A., Klaus, B., Gomez Ramos, B., Prat Oriol, N., Weber, C., & Ehrnhoefer, D. E. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0823-2 · Cited by 101
Axonal Degeneration in AD: The Contribution of Aβ and Tau
Salvadores, N., Gerónimo‐Olvera, C., & Court, F. A. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.581767 · Cited by 101
Pathogenesis of Alzheimer's disease: Involvement of the choroid plexus
Čarná, M., Onyango, I. G., Katina, S., Holub, D., Novotný, J., Nezvedová, M., Jha, D., Nedelská, Z., Lacovich, V., Vyvere, T. V., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.12970 · Cited by 101
Thal, D. R., Attems, J., & Ewers, M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141461 · Cited by 100
Self-citationThe role of norepinephrine in the pathophysiology of schizophrenia
Mäki-Marttunen, V., Andreassen, O. A., & Espeseth, T. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.07.038 · Cited by 100
Braak, H., Ludolph, A. C., Neumann, M., Ravits, J., & Tredici, K. D. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1633-2 · Cited by 99
Self-citationAlzheimer’s disease: A clinical perspective and future nonhuman primate research opportunities
Haque, R. U., & Levey, A. I. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1912954116 · Cited by 99
Porphyromonas gingivalis is a Strong Risk Factor for Alzheimer’s Disease
Kanagasingam, S., Chukkapalli, S. S., Welbury, R. R., & Singhrao, S. K. (2020) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-200250 · Cited by 99
Cassidy, C., Therriault, J., Pascoal, T. A., Cheung, V., Savard, M., Tuominen, L. J., Chamoun, M., McCall, A., Celebi, S., Lussier, F. Z., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01293-6 · Cited by 99
Calderón‐Garcidueñas, L., González-Maciel, A., Reynoso-Robles, R., Hammond, J., Kulesza, R. J., Lachmann, I., Torres‐Jardón, R., Mukherjee, P. S., & Maher, B. A. (2020) · Environmental Research · doi:10.1016/j.envres.2020.110139 · Cited by 98
Reid, M. J., Beltran-Lobo, P., Johnson, L., Perez‐Nievas, B. G., & Noble, W. J. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.572850 · Cited by 98
Structure and Mechanism of Action of Tau Aggregation Inhibitors
Cisek, K. K., Cooper, G., Huseby, C. J., & Kuret, J. (2014) · Current Alzheimer Research · doi:10.2174/1567205011666141107150331 · Cited by 98
Microglial activation occurs late during preclinical Alzheimer's disease
Streit, W. J., Braak, H., Del Tredici, K., Leyh, J., Lier, J., Khoshbouei, H., Eisenlöffel, C., Müller, W., & Bechmann, I. (2018) · Glia · doi:10.1002/glia.23510 · Cited by 98
Self-citationLocal Sleep and Alzheimer’s Disease Pathophysiology
Mander, B. A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.525970 · Cited by 97
An in vivo probabilistic atlas of the human locus coeruleus at ultra-high field
Ye, R., Rua, C., O’Callaghan, C., Jones, P. S., Hezemans, F. H., Kaalund, S. S., Tsvetanov, K. A., Rodgers, C. T., Williams, G. B., Passamonti, L., et al. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117487 · Cited by 97
Lesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes
Gómez-Isla, T., & Frosch, M. P. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00642-9 · Cited by 96
Accuracy of Clinical Diagnosis of Dementia with Lewy Bodies versus Neuropathology
Skogseth, R. E., Hortobágyi, T., Soennesyn, H., Chwiszczuk, L. J., Ffytche, D. H., Rongve, A., Ballard, C. G., & Aarsland, D. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170274 · Cited by 96
Alonso‐Andrés, P., Albasanz, J. L., Ferrer, I., & Martı́n, M. (2018) · Brain Pathology · doi:10.1111/bpa.12592 · Cited by 96
Three-dimensional mapping of neurofibrillary tangle burden in the human medial temporal lobe
Yushkevich, P. A., Muñoz, M., Martin, M. M. I. D. O., Ittyerah, R., Lim, S., Ravikumar, S., Bedard, M. L., Pickup, S., Liu, W., Wang, J., et al. (2021) · Brain · doi:10.1093/brain/awab262 · Cited by 96
Medial perirhinal cortex disambiguates confusable objects
Kivisaari, S. L., TYLER, L. K., Monsch, A. U., & Taylor, K. I. (2012) · Brain · doi:10.1093/brain/aws277 · Cited by 96
Guzmán‐Vélez, E., Diez, I. P., Schoemaker, D., Pardilla‐Delgado, E., Vila‐Castelar, C., Fox‐Fuller, J. T., Baena, A. Y., Sperling, R. A., Johnson, K. A., Lopera, F. J., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2113641119 · Cited by 95
Dang, V., Medina, B., Das, D., Moghadam, S., Martin, K. J., Lin, B., Naik, P. K., Patel, D., Nosheny, R. L., Ashford, J. W., et al. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.05.024 · Cited by 95
Cholesterol as a key player in amyloid β-mediated toxicity in Alzheimer’s disease
Rudajev, V., & Novotny, J. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.937056 · Cited by 94
Evidence of Tau Hyperphosphorylation and Dystrophic Microglia in the Common Marmoset
Rodríguez-Callejas, J. D., Fuchs, E., & Perez‐Cruz, C. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00315 · Cited by 94
Rucco, R., Agosti, V., Jacini, F., Sorrentino, P., Varriale, P., Stefano, M. D., Milan, G., Montella, P., & Sorrentino, G. (2016) · Gait & Posture · doi:10.1016/j.gaitpost.2016.12.021 · Cited by 93
Is tau in the absence of amyloid on the Alzheimer’s continuum?: A study of discordant PET positivity
Weigand, A. J., Bangen, K. J., Thomas, K. R., Delano‐Wood, L., Gilbert, P. E., Brickman, A. M., Bondi, M. W., & Initiative, A. D. N. (2019) · Brain Communications · doi:10.1093/braincomms/fcz046 · Cited by 93
The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a cellular system
Saha, I., Yuste‐Checa, P., Padilha, M. D. S., Guo, Q., Körner, R., Holthusen, H., Trinkaus, V. A., Dudanova, I., Fernández‐Busnadiego, R., Baumeister, W. P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36058-2 · Cited by 93
Abu‐Rumeileh, S., Scholle, L. M., Mensch, A., Großkopf, H., Ratti, A., Kölsch, A., Stoltenburg, G., Conrad, J., Gobbi, A. D., Barba, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57144-7 · Cited by 93
Yao, H., Liu, Y., Zhou, B., Zhang, Z., An, N., Wang, P., Wang, L., Zhang, X., & Jiang, T. (2013) · European Journal of Radiology · doi:10.1016/j.ejrad.2013.03.019 · Cited by 93
Calderón‐Garcidueñas, L., Mora-Tiscareño, A., Franco-Lira, M., Hongtu Zhu, B., Lu, Z., Solorio, E., Torres‐Jardón, R., & D’Angiulli, A. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142685 · Cited by 92
Aβ propagation and strains: Implications for the phenotypic diversity in Alzheimer's disease
Condello, C., & Stöhr, J. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.03.014 · Cited by 92
Thal, D. R., & Tomé, S. O. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.10.006 · Cited by 92
Self-citationStaffaroni, A., Elahi, F., McDermott, D., Marton, K., Karageorgiou, E., Sacco, S., Paoletti, M., Caverzasi, E., Hess, C., Rosen, H., et al. (2017) · Seminars in Neurology · doi:10.1055/s-0037-1608808 · Cited by 91
The complexities of the pathology–pathogenesis relationship in Alzheimer disease
Castellani, R. J., & Perry, G. L. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.009 · Cited by 91
Recent Progress in Alzheimer’s Disease Research, Part 1: Pathology
Hane, F. T., Lee, B. Y., & Leonenko, Z. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160882 · Cited by 92
Gardner, R. C., Rubenstein, R., Wang, K., Korley, F. K., Yue, J. K., Yuh, E. L., Mukherje, P., Valadka, A. B., Okonkwo, D. O., Diaz-Arrastia, R. R., et al. (2018) · Journal of Neurotrauma · doi:10.1089/neu.2018.5694 · Cited by 91
Li, Y., Wang, C., Wang, J., Zhou, Y., Ye, F., Zhang, Y., Cheng, X., Huang, Z., Liu, K., Fei, G., et al. (2019) · Movement Disorders · doi:10.1002/mds.27682 · Cited by 91
Reproducibility of locus coeruleus and substantia nigra imaging with neuromelanin sensitive MRI
Langley, J. A., Huddleston, D. E., Liu, C. J., & Hu, X. P. (2016) · Magnetic Resonance Materials in Physics Biology and Medicine · doi:10.1007/s10334-016-0590-z · Cited by 91
Ardestani, P. M., Evans, A. K., Yi, B., Nguyen, T., Coutellier, L. D., & Shamloo, M. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.01.010 · Cited by 91
Targeting tau: clinical trials and novel therapeutic approaches
VandeVrede, L., Boxer, A. L., & Polydoro, M. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.134919 · Cited by 90
A probabilistic atlas of human brainstem pathways based on connectome imaging data
Tang, Y., Sun, W., Toga, A. W., Ringman, J. M., & Shi, Y. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.12.042 · Cited by 90
Moya, G. E., Rivera, P. D., & Dittenhafer‐Reed, K. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137030 · Cited by 90
Calderón‐Garcidueñas, L., Torres‐Jardón, R., Kulesza, R. J., Mansour, Y., González‐González, L. O., González-Maciel, A., Reynoso-Robles, R., & Mukherjee, P. S. (2020) · Environmental Research · doi:10.1016/j.envres.2020.109137 · Cited by 90
The informed road map to prevention of Alzheimer Disease: a call to arms
McDade, E., Llibre-Guerra, J. J., Holtzman, D. M., Morris, J. C., & Bateman, R. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00467-y · Cited by 89
Ball, M. J., Lukiw, W. J., Kammerman, E. M., & Hill, J. M. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.07.005 · Cited by 89
A Systematic Review of Longitudinal Studies Which Measure Alzheimer’s Disease Biomarkers
Lawrence, E., Vegvari, C., Ower, A. K., Hadjichrysanthou, C., de Wolf, F., & Anderson, R. M. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170261 · Cited by 89
Word-list intrusion errors predict progression to mild cognitive impairment.
Thomas, K. R., Initiative*, T. A. D. N., Eppig, J. S., Edmonds, E. C., Jacobs, D. M., Libon, D. J., Au, R., Salmon, D. P., & Bondi, M. W. (2018) · Neuropsychology · doi:10.1037/neu0000413 · Cited by 89
Respiratory Disease and Lower Pulmonary Function as Risk Factors for Dementia
Russ, T. C., Mika Kivimaki, B., & Batty, G. D. (2020) · CHEST Journal · doi:10.1016/j.chest.2019.12.012 · Cited by 89
Swanson, M. E. V., Scotter, E. L., Smyth, L. C. D., Murray, H. C., Ryan, B., Turner, C. P., Faull, R. L. M., Dragunow, M., & Curtis, M. A. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01047-9 · Cited by 91
Ojo, J. O., Mouzon, B., & Crawford, F. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.06.003 · Cited by 89
Ali, A. M., & Kunugi, H. (2020) · Antioxidants · doi:10.3390/antiox9100937 · Cited by 88
Uhlmann, R. E., Rother, C., Rasmussen, J., Schelle, J., Bergmann, C., Ullrich Gavilanes, E. M., Fritschi, S. K., Buehler, A., Baumann, F., Skodras, A., et al. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-00737-w · Cited by 87
Burnouf, S., Martire, A., Derisbourg, M. J., Laurent, C., Bélarbi, K., Leboucher, A., Fernández-Gómez, F.-J., Troquier, L., Eddarkaoui, S., Grosjean, M., et al. (2012) · Aging Cell · doi:10.1111/acel.12018 · Cited by 87
The Role of Microglia in Sporadic Alzheimer’s Disease
Streit, W. J., Khoshbouei, H., & Bechmann, I. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201248 · Cited by 87
Szot, P. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03476.x · Cited by 87
LoBue, C., Munro, C., Schaffert, J., Didehbani, N., Hart, Batjer, H., & Cullum, C. M. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-190028 · Cited by 86
Regional tau pathology and loneliness in cognitively normal older adults
Uquillas, F. D., Jacobs, H. I. L., Biddle, K. D., Properzi, M. J., Hanseeuw, B. J., Schultz, A. P., Rentz, D. M., Johnson, K. A., Sperling, R. A., & Donovan, N. J. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0345-x · Cited by 86
Neuropathological assessment of the Alzheimer spectrum
Jellinger, K. A. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02232-9 · Cited by 85
Astrocyte–Endotheliocyte Axis in the Regulation of the Blood–Brain Barrier
Pivoriūnas, A., & Verkhratsky, A. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03338-6 · Cited by 85
Origins of Alzheimerʼs disease
Musiek, E. S., & Holtzman, D. M. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32835a30f4 · Cited by 85
Relevance of parahippocampal-locus coeruleus connectivity to memory in early dementia
Jacobs, H. I. L., Wiese, S., van de Ven, V. G., Gronenschild, E. H. B. M., Verhey, F. R. J., & Matthews, P. M. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.10.041 · Cited by 85
Landry, G. J., & Liu-Ambrose, T. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00325 · Cited by 84
Jové, M., Pradas, I., Domínguez-González, M., Ferrer, I., & Pamplona, R. (2018) · Redox Biology · doi:10.1016/j.redox.2018.101082 · Cited by 84
Chen, M.-K., Mecca, A. P., Naganawa, M., Gallezot, J., Toyonaga, T., Mondal, J., Finnema, S. J., Lin, S.-F., O’Dell, R. S., McDonald, J. W., et al. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x211004312 · Cited by 84
Zhang, F., Zhong, R., Li, S., Fu, Z., Wang, R., Wang, T., Huang, Z., & Le, W. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.12.004 · Cited by 85
Simon, E., Obst, J., & Gomez-Nicola, D. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2018.01.059 · Cited by 83
Fesharaki‐Zadeh, A., & Datta, D. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1371213 · Cited by 83
Evidence of intraneuronal Aβ accumulation preceding tau pathology in the entorhinal cortex
Welikovitch, L. A., Carmo, S. D., Maglóczky, Z., Szocsics, P., Lőke, J., Freund, T. F., & Cuello, A. C. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1922-z · Cited by 84
Al‐Shaikh, F. S. H., Duara, R., Crook, J. E., Lesser, E. R., Schaeverbeke, J. M., Hinkle, K. M., Ross, O. A., Ertekin‐Taner, N., Pedraza, O., Dickson, D. W., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.3606 · Cited by 82
Friedberg, J. S., Aytan, N., Cherry, J. D., Xia, W., Standring, O. J., Alvarez, V. E., Nicks, R., Svirsky, S. E., Meng, G., Jun, G., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-59869-5 · Cited by 82
Dahl, M., Bachman, S., Dutt, S., Düzel, S., Bodammer, N., Lindenberger, U., Kühn, S., Werkle‐Bergner, M., & Mather, M. (2023) · Nature Aging · doi:10.1016/j.clinph.2023.02.013 · Cited by 82
Calderón‐Garcidueñas, L., Jewells, V. L., Galaz-Montoya, C. I., van Zundert, B., Pérez-Calatayud, Á. A., Ascencio-Ferrel, E., Valencia‐Salazar, G., Sandoval-Cano, M., Carlos, E., Solorio, E., et al. (2016) · Environmental Research · doi:10.1016/j.envres.2016.06.026 · Cited by 82
Task-evoked pupil dilation and BOLD variance as indicators of locus coeruleus dysfunction
Elman, J. A., Panizzon, M. S., Hagler, D. J., Eyler, L. T., Granholm, E. L., Fennema‐Notestine, C., Lyons, M. J., McEvoy, L. K., Franz, C. E., Dale, A. M., et al. (2017) · Cortex · doi:10.1016/j.cortex.2017.09.025 · Cited by 82
Metadata
- Authors
- Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K.
- Affiliations
- The University of Queensland (AU)
- Corresponding author
- Braak, Heiko
- Venue
- Journal of Neuropathology & Experimental Neurology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-11
- Volume
- 70
- Issue
- 11
- Pages
- 960-969
- ISSN
- 0022-3069 (ISSN-L)
- 1554-6578
- OpenAlex
- W1993023011
- Cited by
- 2,194
- References
- 75
- Citations by year
- 2026: 152 · 2025: 192 · 2024: 260 · 2023: 233 · 2022: 192 · 2021: 235 · 2020: 182 · 2019: 144 · 2018: 121 · 2017: 110 · 2016: 100 · 2015: 85 · 2014: 78 · 2013: 65 · 2012: 42
- FWCI
- 41.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Neuropathology & Experimental Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer Forschung Initiative (10810)
- Deutsche Forschungsgemeinschaft (TH624 4–1)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, pathological staging, tauopathy, neurofibrillary tangles, amyloid plaques, locus coeruleus, brainstem, sporadic Alzheimer's disease, AT8 antibody
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Alzheimer Disease, Brain, Child, Child, Preschool, Female, Humans, Infant, Male, Middle Aged, Neurons, Cohort Studies, Amyloid beta-Peptides, Silver Staining, Neurofibrillary Tangles, tau Proteins, Disease Progression, Statistics, Nonparametric, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
